Gammacan's Oncology Program Highlighted at International Plasma Protein Congress

At a plenary session addressing attendees of the
International Plasma Protein Congress (IPPC 2006) taking place in
Prague on March 7th and 8th, a panel of industry consultants and
opinion leaders discussed the evolving world-wide plasma markets and
highlighted Gammacan's (OTCBB:GCAN) efforts in the field. In the
course of the presentation, the addition on new plasma derived
products was identified as among the key drivers for the continued
growth of the plasma derived protein market.
   Patrick Robert of the Marketing Research Bureau, an industry
thought leader and publisher of the monthly "International
Blood/Plasma News," specifically mentioned Gammacan's (OTCBB: GCAN)
Oncology Program as "an example of an effort that would contribute to
the growth of the IVIg market."
   Vered Caplan, CEO of Gammacan commented: "We were pleasantly
surprised by this unexpected recognition of our efforts in the
development of IVIg-derived plasma products for the treatment of a
variety of cancers. This industry endorsement is a clear signal that
lends further support to our ongoing clinical development programs."

   About Gammacan

   Gammacan is focusing on the commercialization of a revolutionary
anti-cancer immunotherapy that the Company believes will be proven to
be effective in reducing the metastatic spread of a wide range of
cancers. Gammacan's proposed treatment is based on IVIg, a safe,
relatively non-toxic human plasma-based product, currently used to
treat a variety of immune deficiencies and autoimmune diseases. It
works by strengthening the patient's immune system. Many experts
currently view immunotherapy as a future alternative to today's
standard chemotherapy. IVIg is commonly used to treat certain
autoimmune diseases and blood disorders and to replace the antibodies
in people who are unable to produce them. For more information about
Gammacan visit www.Gammacan.com or call the company's headquarters in
Givat Shmuel, Israel at 972 3 577 4475 or 1-866-308-0396 (from North
America)

   About International Blood/Plasma News

   IB/PN is published by the Marketing Research Bureau, an
internationally recognized market research firm specializing in the
collection and analysis of data and market in the area of
plasma-derived and recombinant protein therapies. More information is
available at www.marketingresearchbureau.com.

   Safe Harbor Statement:

   Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this release
include statements regarding: the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IVIG into an effective treatment. Actual
outcomes and the Company's actual results could differ materially from
those in such forward-looking statements. Factors that could cause
actual results to differ materially include risks and uncertainties
such as the inability to finance the planned development of the
technology, inability to hire appropriate staff to develop the
technology, unforeseen technical difficulties in developing the
technology, inability to obtain regulatory approval for human use,
competitors' therapies proving more effective, cheaper or otherwise
preferable for consumers, inability to market the product we produce,
among other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further risk
factors see the risk factors associated with other early stage medical
research and development companies filed with the SEC on Edgar.